Roberts JS, Ferber R, Blacker D, Rumbaugh M, Grill JD. Disclosure of individual research results at federally funded Alzheimer's Disease Research Centers.
ALZHEIMER'S & DEMENTIA (NEW YORK, N. Y.) 2021;
7:e12213. [PMID:
34692986 PMCID:
PMC8515553 DOI:
10.1002/trc2.12213]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
INTRODUCTION
This study describes practices for disclosing individual research results to participants in Alzheimer's disease research.
METHODS
An online survey of clinical core leaders at National Institutes of Health-funded Alzheimer's Disease Research Centers in the United States (response rate: 30/31, 97%) examined return of results practices across nine different types of research results.
RESULTS
Most centers had returned consensus research diagnoses (83%) and neuropsychological test results (73%), with fewer having shared amyloid positron emission tomography (43%), tau imaging (10%), or apolipoprotein E (APOE) genotype (7%) results. Centers reported having disclosed a mean of 3.1 types of results (standard deviation = 2.1; range 0-8). The most commonly cited reason for disclosure was to inform participants' medical decision-making (88%). Disclosure involved multiple professionals and modalities, with neurologists (87%) and in-person visits (85%) most commonplace.
DISCUSSION
Centers varied widely as to whether and how they disclosed research results. Diagnostic and cognitive test results were more commonly returned than genetic or biomarker results.
Collapse